This study is currently recruiting participants.
Number
19-C-0137
Sponsoring Institute
National Cancer Institute (NCI)
Recruitment Detail
Type: Participants currently recruited/enrolled Gender: Male & Female Min Age: 18 Years Max Age: N/A
Referral Letter Required
No
Population Exclusion(s)
Fetuses;Pregnant Women;Children
Keywords
Immune Therapy; Anti-CTLA-4; Receptor Tyrosine Kinases; Anti PD-1; Angiogenesis Inhibitor
Recruitment Keyword(s)
None
Condition(s)
Bladder Cancer; Urothelial Cancer; Penile Cancer; Urogenital Cancer; Sarcomatoid Renal Cell Carcinoma
Investigational Drug(s)
Nivolumab Cabozantinib
Investigational Device(s)
Intervention(s)
Drug: Cabozantinib Drug: Nivolumab Drug: Ipilimumab
Supporting Site
National Cancer Institute
People can get rare genitourinary (GU) tumors in their kidney, bladder, ureters, penis, and other areas. Because these tumors are rare, there is no standard treatment option. Researchers want to see if a combination of drugs can shrink these tumors without significant side effects.
Objective:
To test the effectiveness of cabozantinib with nivolumab and ipilimumab in rare GU cancers that have no standard treatment options.
Eligibility:
Adults 18 and older with a rare, advanced GU tumor.
Design:
This study has 9 different groups based on a type of rare GU cancer and one group based on rare GU tumors with bone-only metastases.
Participants will be screened with a body scan and a bone scan if needed. They will give blood and urine samples. They will answer questions about their level of energy and functionality. Their heart s electrical activity will be monitored. Their tumor will be assessed on body scans. Most of these procedures will be repeated during the study.
Eligible participants will take cabozantinib by mouth daily. They will get nivolumab and ipilimumab in a vein every 3 weeks. After 12 weeks, participants will continue taking cabozantinib by mouth daily and will also get nivolumab every 4 weeks. Ipilimumab will only be given during the first 12 weeks. Cabozantinib and nivolumab can be given for up to 2 years after a response to therapy is achieved. They will keep a medicine diary.
Participants may have a tumor biopsy.
Participants will be followed for 100 days after they stop taking the study drugs. Then they will be contacted every 2 months until 5 years after they started the study.
--Back to Top--
ELIGIBILITY CRITERIA: - Patients must have a histologically confirmed diagnosis of metastatic: small cell/neuroendocrine carcinoma of the bladder; adenocarcinoma of the bladder, or urachal adenocarcinoma, or bladder/urethra clear cell carcinoma; squamous cell carcinoma of the bladder; plasmacytoid urothelial carcinoma; any penile cancer; sarcomatoid renal cell carcinoma; sarcomatoid urothelial carcinoma; renal medullary carcinoma; renal collecting duct carcinoma; bone only urothelial carcinoma or other non-prostate GU tumor - urethra carcinoma, or other miscellaneous histologic variants of the urothelial carcinoma, such as, but not limited to micropapillary, giant cell, lipid-rich, clear cell and nested variants, large cell neuroendocrine carcinoma, lymphoepithelioma-like carcinoma and mixed patterns will be considered, as well as small cell neuroendocrine prostate cancer, malignant testicular Sertoli or Leydig cell tumors, and papillary and chromophobe RCC. - Patients must have measurable disease (RECIST v. 1.1). Patients must have one bone lesion on bone scan for the bone-only cohort. - Patients may have received up to 2 systemic anti-cancer treatments or be treatment naive. Patients with small cell carcinoma should have received a platinum-based combination regimen either as neoadjuvant, adjuvant or first-line treatment. Patients in the bone-only cohort may be urothelial carcinoma histology but must receive standard cisplatin-based chemotherapy (if cisplatin-eligible) - Age greater than or equal to 18 years - Patients must not have had prior treatment with cabozantinib
- Patients must have a histologically confirmed diagnosis of metastatic: small cell/neuroendocrine carcinoma of the bladder; adenocarcinoma of the bladder, or urachal adenocarcinoma, or bladder/urethra clear cell carcinoma; squamous cell carcinoma of the bladder; plasmacytoid urothelial carcinoma; any penile cancer; sarcomatoid renal cell carcinoma; sarcomatoid urothelial carcinoma; renal medullary carcinoma; renal collecting duct carcinoma; bone only urothelial carcinoma or other non-prostate GU tumor - urethra carcinoma, or other miscellaneous histologic variants of the urothelial carcinoma, such as, but not limited to micropapillary, giant cell, lipid-rich, clear cell and nested variants, large cell neuroendocrine carcinoma, lymphoepithelioma-like carcinoma and mixed patterns will be considered, as well as small cell neuroendocrine prostate cancer, malignant testicular Sertoli or Leydig cell tumors, and papillary and chromophobe RCC.
- Patients must have measurable disease (RECIST v. 1.1). Patients must have one bone lesion on bone scan for the bone-only cohort.
- Patients may have received up to 2 systemic anti-cancer treatments or be treatment naive. Patients with small cell carcinoma should have received a platinum-based combination regimen either as neoadjuvant, adjuvant or first-line treatment. Patients in the bone-only cohort may be urothelial carcinoma histology but must receive standard cisplatin-based chemotherapy (if cisplatin-eligible)
- Age greater than or equal to 18 years
- Patients must not have had prior treatment with cabozantinib
Principal Investigator
Referral Contact
For more information: